Evidence map›Paper›PMID 42469872›Full record

ArticleJournal of medical case reports2026

NTRK fusion in metastatic castration-resistant prostate cancer treated with entrectinib: a case report.

Shuichi Tatarano, Akihiko Mitsuke, Yoichi Osako, Takashi Sakaguchi, Satoru Inoguchi, Ryosuke Matsushita, Hirofumi Yoshino, Yasutoshi Yamada, Hideki Enokida

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shuichi TataranoDepartment of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan. taracho@m3.kufm.kagoshima-u.ac.jp.ORCID http://orcid.org/0000-0003-4224-5084
Akihiko MitsukeDepartment of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.
Yoichi OsakoDepartment of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.
Takashi SakaguchiDepartment of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.
Satoru InoguchiDepartment of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.
Ryosuke MatsushitaDepartment of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.
Hirofumi YoshinoDepartment of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.
Yasutoshi YamadaDepartment of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.
Hideki EnokidaDepartment of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe tropomyosin receptor kinase (TRK) inhibitors have demonstrated substantial efficacy in solid tumors harboring neurotrophic tyrosine receptor kinase (NTRK) gene fusions. Although NTRK fusions have been sporadically reported in prostate cancer, their clinical significance and the therapeutic efficacy of TRK inhibitors in this disease remain unclear. We report a case of NTRK fusion-positive metastatic castration-resistant prostate cancer treated with the TRK inhibitor entrectinib. CASE PRESENTATION: A 68-year-old Japanese male with metastatic castration-resistant prostate cancer (mCRPC) experienced disease progression after androgen deprivation therapy, enzalutamide, abiraterone, and docetaxel. Because sufficient tumor tissue was unavailable for comprehensive genomic profiling, circulating cell-free DNA (cfDNA) analysis using FoundationOne

conclusionTo our knowledge, this is the first reported case of NTRK fusion-positive mCRPC treated with entrectinib. This case highlights the potential limitations of cfDNA-based detection of NTRK fusions in prostate cancer and suggests that NTRK fusions detected in cfDNA without tissue validation may not reliably predict clinical benefit from TRK inhibitors in mCRPC. Further studies are required to clarify the biological relevance of NTRK fusions and optimal patient selection for TRK inhibitors in prostate cancer.

Indexed as

Antineoplastic AgentsBenzamidesIndazolesProstatic Neoplasms, Castration-ResistantProtein Kinase InhibitorsReceptor, trkAAgedDisease ProgressionHumansMaleTreatment OutcomeAntineoplastic AgentsBenzamidesentrectinibIndazolesProtein Kinase InhibitorsReceptor, trkAEntrectinibMetastatic castration-resistant prostate cancerNTRK fusionTRK inhibitor

Identifiers

PMID42469872
PMCPMC13660324

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.